Contents

Part I  Percutaneous Absorption

1  Percutaneous Absorption ................................................................. 3
   Michael S. Leo and Howard I. Maibach

2  Animal Models for Percutaneous Absorption .............................. 21
   Eui Chang Jung and Howard I. Maibach

3  Mitigating Dermal Exposure to Agrochemicals ......................... 41
   Robert P. Chilcott

Part II  In Vitro Drug Release

4  Importance of In Vitro Drug Release ........................................... 61
   Vinod P. Shah and Roger L. Williams

5  Diffusion Cell Design ................................................................. 79
   Jon R. Heylings

6  In Vitro Product Quality Tests and Product Performance
   Tests for Topical and Transdermal Drug Products ...................... 81
   Avraham Yacobi, Clarence T. Ueda and Vinod P. Shah

7  Safety and Efficacy Testing of Topical Products; Practical
   Considerations........................................................................ 91
   Rashmikant Mohile
# Contents

## Part III  Bioequivalence of Topical Drug Products

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Challenges in Evaluating Bioequivalence of Topical Dermatological Drug Products</td>
<td>101</td>
<td>Vinod P. Shah and Roger L. Williams</td>
</tr>
<tr>
<td>9</td>
<td>Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies, and Innovative Approaches</td>
<td>113</td>
<td>Isadore Kanfer</td>
</tr>
<tr>
<td>10</td>
<td>Application of Microdialysis in Assessing Cutaneous Bioavailability</td>
<td>153</td>
<td>Eva Benfeldt</td>
</tr>
</tbody>
</table>

## Part IV  Bioequivalence: Targeted Drug Delivery

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Follicular Drug Penetration</td>
<td>169</td>
<td>Jürgen Lademann and Alexa Patzelt</td>
</tr>
<tr>
<td>12</td>
<td>Development of Pilosebaceous Unit-Targeted Drug Products</td>
<td>181</td>
<td>Guang Wei Lu, Kevin S. Warner and Fangjing Wang</td>
</tr>
<tr>
<td>13</td>
<td>Deep Percutaneous Penetration into Muscles and Joints: Update</td>
<td>217</td>
<td>Vladyslava Doktor, Christine M. Lee and Howard I. Maibach</td>
</tr>
<tr>
<td>14</td>
<td>Efficacy and Toxicity of Microneedle-Based Devices</td>
<td>237</td>
<td>Michael S. Leo, Hadar A. Lev-Tov, Faranak Kamangar, Howard I. Maibach and Raja K. Sivamani</td>
</tr>
</tbody>
</table>

## Part V  Transdermal Drugs and Modelling

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Mathematical Models for Topical and Transdermal Drug Products</td>
<td>249</td>
<td>Yuri G. Anissimov and Michael S. Roberts</td>
</tr>
<tr>
<td>16</td>
<td>Transdermal Patches: An Industrial Perspective on the Relevance of In Vitro Skin Permeation Studies and Approaches on Design of Manufacturing Processes</td>
<td>299</td>
<td>Björn Schurad and Marieke Gosau</td>
</tr>
<tr>
<td>17</td>
<td>Transdermal Drug Delivery Systems</td>
<td>319</td>
<td>Vinod P. Shah and Roger L. Williams</td>
</tr>
</tbody>
</table>
Part VI  Clinical Studies and Bioequivalence

18 Dermal Estradiol and Testosterone Transfer in Man: Existence, Models, and Strategies for Prevention .................................. 331
   Aaron Gandhi, K. L. Busse and Howard I. Maibach

19 Effects of Occlusion on Dermal Drug Delivery: Implications for Bioequivalence Measurement .................................. 351
   Nilab Osman and Howard I. Maibach

20 Challenges with Clinical Endpoints—Bioequivalence ......................... 361
   Garrett Coman, Nicholas Blickenstaff and Howard I. Maibach

21 Clinical Considerations of Bioequivalence for Topical Dermatologic Drugs .................................................. 371
   Jessica Schweitzer and Howard I. Maibach

Part VII  Guidelines and Workshop Report

22 OECD Test Guideline 428—A Method for In Vitro Percutaneous Absorption Measurement? .................................. 381
   John Jenner

23 Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products: Current Challenges and Future Prospects ...... 389
   Vinod P. Shah, Avraham Yacobi and Majella E. Lane

Index ........................................................................................................ 399
Topical Drug Bioavailability, Bioequivalence, and Penetration
Shah, V.; Maibach, H.I.; Jenner, J. (Eds.)
2014, XIII, 402 p. 64 illus., 16 illus. in color., Hardcover
ISBN: 978-1-4939-1288-9